List view / Grid view
Over the last 10 years, there has been an important change of focus in pharma towards biotech products and personalised therapies. These important new treatments are now emerging into manufacturing, with implications for the way that quality is monitored, managed and assured. Dr Eduard Cayón sets out some practical advice.
Keith A Zullow and Jenny J Zhang from Goodwin Procter examine upcoming US pharmaceutical regulation and how, if passed, it could impact European pharma/biopharma looking to access the US market.
Sandoz will invest €50 million in new Austrian finished dosage form manufacturing site, to support the global demand for penicillin products.
4 November 2022 | By
Could the new wave of taxane chemotherapies succeed where traditional chemotherapies have failed? Colin Freund, Chief Executive Officer of Modra Pharmaceuticals, reveals the benefits of this emerging generation of anticancer treatment.
CPhI’s 2022 Pharma Index survey showed growth and quality scores improved considerably for every market, with India being the overall winner.
What’s new in the cell and gene therapy landscape? What is the role of quality control in efforts to scale up manufacturing of CGT products and alleviate talent constraints? Find out more in this podcast with bioMérieux…
First-in-human clinical verification is one of the first critical milestones in drug development. Abhijeet Sinha, Senior Scientist at Lonza Small Molecules, exemplifies the imperative of solving drug development challenges in the early phases.
27 October 2022 | By
Articles in this drug formulation In-Depth Focus explore the design of formulations using cyclodextrins, plus the development of orally-delivered taxane chemotherapies.
The centre will help prepare engineers and advance research in this emerging industry, according to Gallogly College of Engineering’s Associate Dean for Research.
COVID-19 vaccine key players back a new proposal ensuring vaccines for future pandemics are equally distributed to all priority populations.
As industry leaders seek strategies to build supply chain resilience, multi-sourcing is driving the adoption of alternative solutions like rFC.
Identification of environmental isolates is a regular requirement in pharmaceutical manufacturing, and strain differentiation can be valuable in a variety of circumstances. There have been huge advances in the technology available for sequencing bacterial genomes, which has fed through to the analyses that are available to pharmaceutical microbiologists. NCIMB’s Identification…
A collaboration agreement between Gilead and biopharma company MacroGenics aims to develop MGD024, a bispecific antibody for treatment of blood cancers.
Rising demand for cancer drugs, combined with high in-house manufacturing costs is driving growth in the high-potency API outsourcing market.
Sanofi’s Japan-based manufacturing site near Tokyo will be sold to a European contract development and manufacturing organisation.
